15
Jun
2009
Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Dengue, X - HPV, X - RSV, X - Vaccines, XX - NJ
VaxInnate (Cranbury, NJ) a clinical-stage vaccine company focused on infectious disease including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus, closed a $30M Series D financing. Participants include Wellcome Trust, New Leaf Venture Partners, Canaan Partners, HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures and CHL Medical Partners.